Ilyas Sahin, MD, discusses the Northstar Response assay and the future of precision oncology in patients with advanced gastrointestinal cancer.
Ilyas Sahin, MD
Advertisement
Articles by Ilyas Sahin, MD
Ilyas Sahin, MD, discusses the potential utility of Northstar Response assay in patients with advanced gastrointestinal cancer.
Ilyas Sahin, MD, discusses an assessment of the Northstar Response in patients with advanced gastrointestinal cancer undergoing active treatment.
Ilyas Sahin, MD, discusses the investigation of milademetan in combination with imipridone ONC201 as a synergistic combination in solid tumors.
Ilyas Sahin, MD, discusses the background and findings of the phase 2 IMbrave 151 trial in advanced biliary tract cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5